H. Terence Cook
Researcher
Also affiliated: University of London (2008); Mayo Clinic (2015); Imperial College Healthcare NHS Trust (2012–2025); Chiba University (2002); University of Washington (1996); University of Cambridge (2019–2020); The Royal Free Hospital (2009); Cancer Research UK (2008); Hammersmith Hospital (1998–2024); Imperial Valley College (2010); Cambridge University Hospitals NHS Foundation Trust (2019–2020); Institute for Diabetes Discovery (2009); Papworth Hospital NHS Foundation Trust (2020); Kids' Brain Tumor Cure Foundation (2005); North West London Pathology (2025); Institut de Transplantation Urologie en Nephrologie (2011); St Mary's Hospital (1994); Metabolism and Renal Physiology (1999–2006); University of Washington Applied Physics Laboratory (1996); Oxford BioMedica (United Kingdom) (2003); Centre for Inflammation Research (2010–2022); Genomics (United Kingdom) (2013); Addenbrooke's Hospital (2019–2020); Roland Hill (United Kingdom) (2024); NIHR Cambridge Biomedical Research Centre (2019); University College London (2009–2024); Imperial College London (1998–2025); Seattle University (1996); Columbia University (2013); Cardiff University (2024)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
H. Terence Cook's research focuses on the role of the complement system in kidney diseases, particularly IgA nephropathy and C3 glomerulopathy. His work investigates the activation pathways of complement and their association with disease progression and clinical outcomes.
His publications examine various aspects of kidney pathology, including the impact of histologic parameters on outcomes in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis, as well as the association of histologic and clinical factors with kidney outcomes in IgA vasculitis nephritis. Cook has also explored the effects of rare kidney diseases on kidney failure, drawing on data from national registries. His research includes evaluating the efficacy of targeted therapies, such as the factor D inhibitor danicopan, for specific complement-mediated kidney conditions.
Cook is a highly cited researcher with an h-index of 60 and over 16,000 citations across 168 publications. He leads a research group at the University of Arkansas for Medical Sciences and collaborates with other faculty members, including Rupak Pathak, Enoch K. Larrey, and Edith Nathalie Pineda.
Metrics
- h-index: 61
- Publications: 168
- Citations: 16,533
Selected Publications
-
Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity (2025)
-
Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation (2025)
Collaboration Network
Top Collaborators
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
- Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity
Similar Researchers
Based on overlapping research topics